Galactosylated Polymer/Gold Nanorods Nanocomposites for Sustained and Pulsed Chemo-Photothermal Treatments of Hepatocarcinoma

Galactosylated Polymer/Gold Nanorods Nanocomposites for Sustained and Pulsed Chemo-Photothermal Treatments of Hepatocarcinoma

In this paper, we propose a rational design of a hybrid nanosystem capable of locally delivering a high amount of hydrophobic anticancer drugs (sorafenib or lenvatinib) and heat (hyperthermia) in a remote-controlled manner. We combined in a unique nanosystem the excellent NIR photothermal conversion...

Full description

Bibliographic Details
Main Authors:	Gaetano Giammona, Salvatore Emanuele Drago, Giovanna Calabrese, Paola Varvarà, Maria Giovanna Rizzo, Nicolò Mauro, Giuseppe Nicotra, Sabrina Conoci, Giovanna Pitarresi
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	Pharmaceutics
Subjects:	polyaspartamide gold nanorods sorafenib lenvatinib nanoparticles drug delivery
Online Access:	https://www.mdpi.com/1999-4923/14/11/2503

Similar Items

Design of New Polyaspartamide Copolymers for siRNA Delivery in Antiasthmatic Therapy
by: Emanuela Fabiola Craparo, et al.
Published: (2020-01-01)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
by: Burgio V, et al.
Published: (2021-12-01)

Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population
by: Shou-Wu Lee, et al.
Published: (2022-03-01)

A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario
by: Dipasquale A, et al.
Published: (2021-04-01)

Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis
by: Vikash Jaiswal, et al.
Published: (2023-12-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis
by: Sagmeister P, et al.
Published: (2022-07-01)

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
by: Jaejun Lee, et al.
Published: (2020-12-01)

Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
by: Amit Mahipal, et al.
Published: (2019-07-01)

Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma
by: Kazufumi Kobayashi, et al.
Published: (2021-12-01)

Hybrid Gold Nanorod-Based Nanoplatform with Chemo and Photothermal Activities for Bimodal Cancer Therapy
by: Lilia Arellano-Galindo, et al.
Published: (2022-10-01)

Synthesis and Characterization of Gold Nanorods and Their Application for Photothermal Cell Damage [Retraction]
by: Samim M, et al.
Published: (2022-10-01)

Online searches for hepatocellular carcinoma drugs mirror prescription trends across specialties and changes in guideline recommendations
by: Philipp Berning, et al.
Published: (2024-02-01)

The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence
by: Maria Cerreto, et al.
Published: (2023-09-01)

Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer
by: Yu-Ling Lu, et al.
Published: (2021-07-01)

Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates
by: Kenji Imai, et al.
Published: (2023-08-01)

Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges
by: Emanuele Rinninella, et al.
Published: (2020-10-01)

Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma
by: Hitomi Takada, et al.
Published: (2021-08-01)

Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
by: Shijie Wang, et al.
Published: (2022-11-01)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
by: Yanjun Cui, et al.
Published: (2022-08-01)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
by: Hsueh-Chien Chiang, et al.
Published: (2023-01-01)

Impact of Age-Related Genetic Differences on the Therapeutic Outcome of Papillary Thyroid Cancer
by: Seok-Mo Kim, et al.
Published: (2020-02-01)

Enhanced therapeutic efficacy of drug encapsulated folic acid conjugated graphene oxide - gold nanorods for chemo-photothermal therapeutics of cervical cancer
by: Yu Chen, et al.
Published: (2021-01-01)

Metal organic framework-coated gold nanorod as an on-demand drug delivery platform for chemo-photothermal cancer therapy
by: Junfeng Huang, et al.
Published: (2021-07-01)

Synergistic chemo-photothermal therapy using gold nanorods supported on thiol-functionalized mesoporous silica for lung cancer treatment
by: Maryam Deinavizadeh, et al.
Published: (2024-02-01)

Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
by: Naoki Fukuda, et al.
Published: (2021-05-01)

Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma
by: Pang-Shuo Perng, et al.
Published: (2022-03-01)

First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
by: Domenico Ciliberto, et al.
Published: (2023-08-01)

Erratum: Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
by: Frontiers Production Office
Published: (2023-04-01)

Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
by: Lei Jiang, et al.
Published: (2023-02-01)

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
by: Jia Luo, et al.
Published: (2022-12-01)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
by: Urbano Anido Herranz
Published: (2022-10-01)

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
by: Chen B, et al.
Published: (2022-12-01)

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
by: Yongkang Xu, et al.
Published: (2022-09-01)

Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2021-01-01)

Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma
by: Arndt Vogel, et al.
Published: (2021-07-01)

Gold Nanorod-Assisted Photothermal Therapy and Improvement Strategies
by: Mitchell Lee Taylor, et al.
Published: (2022-05-01)

A Spike-like Self-Assembly of Polyaspartamide Integrated with Functionalized Nanoparticles
by: Sa Ra Han, et al.
Published: (2024-01-01)

Oxidative Stress-Induced Silver Nano-Carriers for Chemotherapy
by: Minh Phuong Nguyen, et al.
Published: (2022-11-01)

Diffusion mechanism and effect of mass transfer limitation during the adsorption of CO2 by polyaspartamide in a packed-bed unit
by: Kelvin O. Yoro, et al.
Published: (2020-01-01)